Evidence map›Paper›PMID 40423776›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers.

Jiajun Ye, Shu Yang, Yu Liu, Zhiyong Quan, Mingru Zhang, Guiyu Li, Zifan Zhu, Jia Wang, Taoqi Ma, Junlin Wang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiajun YeDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Shu YangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Yu LiuPeking University-Tsinghua University Center for Life Sciences, Peking University, Beijing, 100871, China.
Zhiyong QuanDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Mingru ZhangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Guiyu LiDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Zifan ZhuDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Jia WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Taoqi MaDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Junlin WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Zhibo LiuPeking University-Tsinghua University Center for Life Sciences, Peking University, Beijing, 100871, China. zbliu@pku.edu.cn.
Jing WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. 13909245902@163.com.
Fei KangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. fmmukf@qq.com.

Funding

National Natural Science Foundation of China 82122033National Natural Science Foundation of China 82402323National Natural Science Foundation of China 92259304Shaanxi Province Key Industry Innovation Chain 2024SF-ZDCYL-02-06
6 · The paper itself

Abstract

purposeFibroblast activation protein (FAP) has emerged as one of the most promising theranostic targets. FT-FAPI, a potential FAP-targeted probe with enhanced tumor-targeting ability using an organotrifluoroborate linker, was verified for the biological effect in cell and animal experiments in previous work. However, the differences in pharmacokinetic profiles, biodistribution and dosimetry of FT-FAPI under multiple nuclides labeling in animals and humans is unclear. In this study, we sought to explore the discrepancies in the performance of FT-FAPI after labeling with different radioisotopes and to compare

methodsPreparation and quality control of

results

conclusionThe pharmacokinetics of FT-FPAI varies depending on the labeled nuclide. Compared to

Indexed as

GelatinasesMembrane ProteinsRadiopharmaceuticalsSerine EndopeptidasesAdultAnimalsEndopeptidasesFemaleFibroblast Activation Protein AlphaFluorine RadioisotopesGallium RadioisotopesHealthy VolunteersHumansIsotope LabelingLutetiumMaleEndopeptidasesFibroblast Activation Protein AlphaFluorine RadioisotopesGallium RadioisotopesGelatinasesLutetiumLutetium-177Membrane ProteinsRadioactive TracersRadioisotopesRadiopharmaceuticalsSerine EndopeptidasesDosimetryFibroblast activation proteinFT-FAPIOrganotrifluoroborateTheranostics

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.